Expression of EGFR, Grb2, p-mTOR and VEGF in human colorectal cancer tissues

Academic Journal of Second Military Medical University

Volumn 30, Issue 7, 2009, Pages 775-779

  Xiang, Hong Gang ^a   Wang, Qiang ^a   Hu, Zhi Qian ^a   Xu, Jian ^a   Wang, Wei Jun ^a   Wei, Zi Ran ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cojorectal neoplasms; EGFR; Grb2; p mTOR; Tissue microarray; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; COLORECTAL CANCER; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

EID: 68349090274     PISSN: 0258879X     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1008.2009.00775     Document Type: Article

References (21)

1. Adjei A A. Novel combinations based on epidermal growth factor receptor inhibition[J]. Clin Cancer Res, 2006,12(14 Pt 2): 4446s-4450s.
2. Edwards L A, Verreault M, Thiessen B, Dragowska W H, Hu Y, Yeung J H, et al. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells[J]. Mol Cancer Ther, 2006,5:645-654.
3. Strimpakos A S, Karapanagiotou E M, Saif M W, Syrigos K N. The role of mTOR in the management of solid tumors: an overview[J]. Cancer Treat Rev, 2009,35:148-159.
4. Xiang H G, Hu Z Q, Wang W J, Xu J, Zhang J, Xu C, et al. Expression of phosphorylated mammalian target of rapamycin in colorectal cancer and its significance[J]. Acad J Sec Mil Med Univ, 2009,30:517-520.
5. Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets [J]. Eur J Cancer, 2006,42:290-294. (Pubitemid 43132883)
6. Hezel A F, Ryan D P. Emerging therapies for colorectal cancer [J]. Expert Opin Investig Drugs, 2007,16:867-876.
7. Adjei A A, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy[J]. J Clin Oncol, 2005,23:5386-5403. (Pubitemid 46206992)
8. Nicholson R I, Gee J M, Harper M E. EGFR and cancer prognosis[J]. Eur J Cancer, 2001,37(Suppl 4):S9-S15.
9. Dei Tos A P. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor[J]. Int J Biol Markers, 2007,22(1 Suppl 4):S3-S9. (Pubitemid 46730018)
10. Dharmawardana P G, Peruzzi B, Giubellino A, Burke T R Jr, Bottaro D P. Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy [J]. Anticancer Drugs, 2006,17:13-20.
11. Pan Z, Wang J, Yin X, Xie P, Yang J, Jiang J, et al. The function study on the interaction between Grb2 and AMPK[J]. Mol Cell Biochem, 2008,307(1-2):121-127. (Pubitemid 350238654)
12. Zang X P, Siwak D R, Nguyen T X, Tari A M, Pento J T. KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk 1, 2[J]. Clin Exp Metastasis, 2004,21:437-443.
13. Weichhart T, Säemann M D. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications[J]. Ann Rheum Dis, 2008,67(Suppl 3):iii70-iii74.
14. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier K M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response[J]. Immunity, 2008,29:565-577.
15. Walid S, Eisen R, Ratcliffe D R, Dai K, Hussain M M, Ojakian G K. The PI3-kinase and mTOR signaling pathways are important modulators of epithelial tubule formation[J]. J Cell Physiol, 2008,216:469-479. (Pubitemid 351898475)
16. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer[J]. Br J Cancer, 2004,91:1420-1424. (Pubitemid 39486341)
17. Kremer C L, Klein R R, Mendelson J, Browne W, Samadzedeh L K, Vanpatten K, et al. Expression of mTOR signaling pathway markers in prostate cancer progression[J]. Prostate, 2006, 66:1203-1212. (Pubitemid 44175342)
18. Lang S A, Gaumann A, Koehl G E, Seidel U, Bataille F, Klein D, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model[J]. Int J Cancer, 2007,120:1803-1810. (Pubitemid 46399369)
19. Faried L S, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy[J]. Mol Carcinog, 2008,47:446-457. (Pubitemid 351822303)
20. Cascinu S, Staccioli M P, Gasparini G, Giordani P, Catalano V, Ghiselli R, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer[J]. Clin Cancer Res, 2000,6:2803-2807. (Pubitemid 30482120)
21. Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells[J]. Oncogene, 2007,26:2255-2262. (Pubitemid 46572812)